Vorinostat
A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which vorinostat will be combined with other drugs.
Save A Brain Foundation
The Save A Brain Foundation is a 501(c)(3) non-profit organization with the goals of raising awareness of Glioblastoma Multiforme, the most common type of primary brain tumor, as well as raising money in hopes of finding a cure for this terminal disease. To date, the foundation has raised tens of thousands of dollars for brain cancer research.